Publication Date:
2009-06-26
Description:
Genome-wide copy number analyses of human cancers identified a frequent 5p13 amplification in several solid tumour types, including lung (56%), ovarian (38%), breast (32%), prostate (37%) and melanoma (32%). Here, using integrative analysis of a genomic profile of the region, we identify a Golgi protein, GOLPH3, as a candidate targeted for amplification. Gain- and loss-of-function studies in vitro and in vivo validated GOLPH3 as a potent oncogene. Physically, GOLPH3 localizes to the trans-Golgi network and interacts with components of the retromer complex, which in yeast has been linked to target of rapamycin (TOR) signalling. Mechanistically, GOLPH3 regulates cell size, enhances growth-factor-induced mTOR (also known as FRAP1) signalling in human cancer cells, and alters the response to an mTOR inhibitor in vivo. Thus, genomic and genetic, biological, functional and biochemical data in yeast and humans establishes GOLPH3 as a new oncogene that is commonly targeted for amplification in human cancer, and is capable of modulating the response to rapamycin, a cancer drug in clinical use.〈br /〉〈br /〉〈a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2753613/" target="_blank"〉〈img src="https://static.pubmed.gov/portal/portal3rc.fcgi/4089621/img/3977009" border="0"〉〈/a〉 〈a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2753613/" target="_blank"〉This paper as free author manuscript - peer-reviewed and accepted for publication〈/a〉〈br /〉〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Scott, Kenneth L -- Kabbarah, Omar -- Liang, Mei-Chih -- Ivanova, Elena -- Anagnostou, Valsamo -- Wu, Joyce -- Dhakal, Sabin -- Wu, Min -- Chen, Shujuan -- Feinberg, Tamar -- Huang, Joseph -- Saci, Abdel -- Widlund, Hans R -- Fisher, David E -- Xiao, Yonghong -- Rimm, David L -- Protopopov, Alexei -- Wong, Kwok-Kin -- Chin, Lynda -- 5-T32-AR07098-31/AR/NIAMS NIH HHS/ -- P50 CA090578/CA/NCI NIH HHS/ -- P50 CA093683/CA/NCI NIH HHS/ -- P50 CA093683-06A20011/CA/NCI NIH HHS/ -- P50 CA93683/CA/NCI NIH HHS/ -- R0-1 CA 114277/CA/NCI NIH HHS/ -- R01 AG2400401/AG/NIA NIH HHS/ -- R01 CA093947/CA/NCI NIH HHS/ -- R01 CA093947-08/CA/NCI NIH HHS/ -- R01 CA114277/CA/NCI NIH HHS/ -- R01 CA114277-04/CA/NCI NIH HHS/ -- R01 CA122794/CA/NCI NIH HHS/ -- R01 CA122794-03/CA/NCI NIH HHS/ -- R01 CA93947/CA/NCI NIH HHS/ -- T32 AR007098/AR/NIAMS NIH HHS/ -- T32 AR007098-32/AR/NIAMS NIH HHS/ -- England -- Nature. 2009 Jun 25;459(7250):1085-90. doi: 10.1038/nature08109.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/19553991" target="_blank"〉PubMed〈/a〉
Keywords:
Animals
;
Antibiotics, Antineoplastic/*pharmacology
;
Cell Line, Tumor/drug effects
;
DNA-Binding Proteins/genetics
;
Female
;
Gene Knockdown Techniques
;
Humans
;
Membrane Proteins/genetics/*metabolism
;
Mice
;
Mice, Nude
;
Neoplasms/*physiopathology
;
Protein Kinases/genetics/*metabolism
;
Saccharomyces cerevisiae/genetics
;
*Signal Transduction
;
Sirolimus/*pharmacology
;
TOR Serine-Threonine Kinases
;
Transcription Factors/genetics
Print ISSN:
0028-0836
Electronic ISSN:
1476-4687
Topics:
Biology
,
Chemistry and Pharmacology
,
Medicine
,
Natural Sciences in General
,
Physics
Permalink
